Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing intractable migraine with naratriptan.

R Michael Gallagher1, Loretta Mueller

  • 1University Headache Center, Moorestown, NJ 08057, USA.

Headache
|September 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Smoking in women.

Journal of osteopathic medicine·2023
Same author

A Vaccinia-based system for directed evolution of GPCRs in mammalian cells.

Nature communications·2023
Same author

Generation and preclinical characterization of an antibody specific for SEMA4D.

mAbs·2015
Same author

Influenza enhances caspase-1 in bronchial epithelial cells from asthmatic volunteers and is associated with pathogenesis.

The Journal of allergy and clinical immunology·2012
Same author

Cerium dioxide nanoparticles can interfere with the associated cellular mechanistic response to diesel exhaust exposure.

Toxicology letters·2012
Same author

Toxic effects of brake wear particles on epithelial lung cells in vitro.

Particle and fibre toxicology·2009
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
Same journal

American Headache Society 68th Annual Scientific Meeting June 4-7, 2026, Orlando, Florida.

Headache·2026
Same journal

In Memoriam-Doctor J. Keith Campbell.

Headache·2026
Same journal

Hypothalamus as a conductor of the migraine prodrome: A narrative review.

Headache·2026
Same journal

New academic year in Headache.

Headache·2026
Same journal

Essential readings in headache medicine: Top 10 educational articles from 2025.

Headache·2026
See all related articles

Naratriptan 2.5 mg twice daily effectively treated intractable migraine in 79% of patients. This short-term daily administration shows promise for terminating prolonged migraine attacks, offering relief for status migrainosus.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Intractable migraine poses a significant therapeutic challenge.
  • Some migraine attacks persist despite treatment, becoming status migrainosus.

Purpose of the Study:

  • To evaluate the efficacy of naratriptan 2.5 mg twice daily for intractable migraine.
  • To assess naratriptan's effectiveness in terminating prolonged migraine attacks.

Main Methods:

  • A review of 24 patients with intractable migraine treated with naratriptan twice daily.
  • Patients could continue prior effective prophylactic medications.

Main Results:

  • Seventy-nine percent (19/24) of patients showed improvement.
  • Twelve patients had an excellent response (pain cessation), and 7 had a partial response.

Related Experiment Videos

  • Five patients did not respond to the treatment.

    • Conclusions:

    • Short-term, daily naratriptan administration may effectively terminate status migrainosus.
    • Naratriptan offers a potential treatment option for prolonged and intractable migraine episodes.